Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes

Table 3 Results of multivariate logistic regression analysis

	Beta	Standard error	Odds ratio	95% CI		P-value
	Beta	Standard error	Odds ratio	Lower	Upper
AIP	1.621	0.441	5.057	2.133	11.991	< 0.001
Age, years	− 0.018	0.011	0.982	0.961	1.003	0.096
Gender (male)	− 1.052	0.251	0.347	0.212	0.567	< 0.001
Duration of DM, years	− 0.034	0.015	0.967	0.939	0.996	0.026
SBP, mmHg	0.000	0.001	1.000	0.997	1.002	0.909
DBP, mmHg	− 0.001	0.015	0.999	0.970	1.029	0.949
Waist/hip	− 0.358	1.619	0.699	0.029	16.698	0.825
HOMA-IR	0.164	0.054	1.178	1.059	1.311	0.003
FBS, mg/dl	0.000	0.003	1.000	0.995	1.005	0.868
AST, U/L	− 0.028	0.019	0.973	0.938	1.009	0.142
ALT, U/L	0.055	0.011	1.057	1.034	1.080	< 0.001
ALKP, U/L	− 0.003	0.001	0.997	0.995	1.000	0.039
GGT, U/L	0.006	0.004	1.006	0.999	1.014	0.099
Anti-lipid therapy ( +)	− 0.312	0.235	0.732	0.461	1.160	0.184

AIP atherogenic index of plasma, SBP systolic blood pressure, DBP diastolic blood pressure, HOMA-IR homeostatic model assessment of insulin resistance, HDL high-density lipoprotein, FBS fasting blood glucose, AST aspartate transaminase, ALT alanine transaminase, ALP alkaline phosphatase, GGT gamma-glutamyl transferase, anti-lipid therapy ( +) patients received anti-lipid therapy

ISSN: 2047-783X